Evidence map›Paper›PMID 38634876›Full record

ArticleEuropean radiology2024

Radiomics and machine learning for renal tumor subtype assessment using multiphase computed tomography in a multicenter setting.

Annemarie Uhlig, Johannes Uhlig, Andreas Leha, Lorenz Biggemann, Sophie Bachanek, Michael Stöckle, Mathias Reichert, Joachim Lotz, Philip Zeuschner, Alexander Maßmann

Abstract readMulticenter Study
In one paragraph

Article in European radiology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Review
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. State of the art review of AI in renal imaging.Abdominal radiology (New York) · 2025
    Review
  13. Review
  14. Article
  15. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Annemarie Uhlig *Department of Urology, University Medical Center Goettingen, Goettingen, Germany. Annemarie.uhlig@med.uni-goettingen.de.ORCID http://orcid.org/0000-0001-7305-9271
Johannes Uhlig *Department of Clinical and Interventional Radiology, University Medical Center Goettingen, Goettingen, Germany.
Andreas LehaDepartment of Medical Statistics, University Medical Center Goettingen, Goettingen, Germany.
Lorenz BiggemannDepartment of Clinical and Interventional Radiology, University Medical Center Goettingen, Goettingen, Germany.
Sophie BachanekDepartment of Clinical and Interventional Radiology, University Medical Center Goettingen, Goettingen, Germany.
Michael StöckleDepartment of Urology and Pediatric Urology, Saarland University, Homburg, Germany.
Mathias ReichertDepartment of Urology, University Medical Center Goettingen, Goettingen, Germany.
Joachim LotzDepartment of Cardiac Imaging, University Medical Center Goettingen, Goettingen, Germany.
Philip Zeuschner *Department of Urology and Pediatric Urology, Saarland University, Homburg, Germany.
Alexander Maßmann *Department of Radiology and Nuclear Medicine, Robert-Bosch-Clinic, Stuttgart, Germany.

Funding

Universitätsmedizin Göttingen NA
6 · The paper itself

Abstract

objectivesTo distinguish histological subtypes of renal tumors using radiomic features and machine learning (ML) based on multiphase computed tomography (CT). MATERIAL AND

methodsPatients who underwent surgical treatment for renal tumors at two tertiary centers from 2012 to 2022 were included retrospectively. Preoperative arterial (corticomedullary) and venous (nephrogenic) phase CT scans from these centers, as well as from external imaging facilities, were manually segmented, and standardized radiomic features were extracted. Following preprocessing and addressing the class imbalance, a ML algorithm based on extreme gradient boosting trees (XGB) was employed to predict renal tumor subtypes using 10-fold cross-validation. The evaluation was conducted using the multiclass area under the receiver operating characteristic curve (AUC). Algorithms were trained on data from one center and independently tested on data from the other center.

resultsThe training cohort comprised n = 297 patients (64.3% clear cell renal cell cancer [RCC], 13.5% papillary renal cell carcinoma (pRCC), 7.4% chromophobe RCC, 9.4% oncocytomas, and 5.4% angiomyolipomas (AML)), and the testing cohort n = 121 patients (56.2%/16.5%/3.3%/21.5%/2.5%). The XGB algorithm demonstrated a diagnostic performance of AUC = 0.81/0.64/0.8 for venous/arterial/combined contrast phase CT in the training cohort, and AUC = 0.75/0.67/0.75 in the independent testing cohort. In pairwise comparisons, the lowest diagnostic accuracy was evident for the identification of oncocytomas (AUC = 0.57-0.69), and the highest for the identification of AMLs (AUC = 0.9-0.94)

conclusionRadiomic feature analyses can distinguish renal tumor subtypes on routinely acquired CTs, with oncocytomas being the hardest subtype to identify. CLINICAL RELEVANCE STATEMENT: Radiomic feature analyses yield robust results for renal tumor assessment on routine CTs. Although radiologists routinely rely on arterial phase CT for renal tumor assessment and operative planning, radiomic features derived from arterial phase did not improve the accuracy of renal tumor subtype identification in our cohort.

Indexed as

Kidney NeoplasmsMachine LearningTomography, X-Ray ComputedAdultAgedAlgorithmsCarcinoma, Renal CellFemaleHumansMaleMiddle AgedRadiographic Image Interpretation, Computer-AssistedRadiomicsRetrospective StudiesComputersMachine learningMultidetector computed tomographyRadiomicsRenal cell carcinoma

Identifiers

PMID38634876
PMCPMC11399155

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.